MedTech News
.................... by Andrew Celentano

BD picks up CE mark for next-gen stent graft
BD (NYSE:BDX) announced today that it received CE mark approval for its Liverty TIPS stent graft system.

Supira gets FDA green light to conduct ventricular assist device study
Supira Medical announced today that it received FDA approval to initiate a new trial of its percutaneous ventricular assist device (pVAD).

MRI technique enables long-term tracking of transplanted stem cell-derived heart cells
Researchers at the Institute of Biomedical Engineering at the University of Toronto have demonstrated a new way to monitor transplanted stem-cell-derived heart cells using magnetic resonance imaging (MRI).

Gene-edited stem cells help five blood disorder patients stop transfusions in clinical trial
Stem cell transplantation could be a rapid and effective way to restore hemoglobin production in individuals with the blood disorder β-thalassaemia.

Sequencing method exposes hidden gaps in immune signaling by tracking RNA and protein together
A new single-cell technology is giving scientists their clearest view yet of immune cell behavior—capturing not just genetic intent, but real-time activity.

Researchers use earbuds to monitor heart health
Carnegie Mellon researchers have proven that widely available earbuds can double as heart-monitoring devices, capturing subtle cardiac activity with near-clinical accuracy and potentially expanding access to long-term, at-home care.

How the microprotein BRICK1 repairs and protects the heart after a heart attack
Now, a research team led by Prof. Dr. Kai Wollert, Head of Molecular and Translational Cardiology at the Department of Cardiology and Angiology at Hannover Medical School (MHH), has discovered that a microprotein called BRICK1 plays a key role in this process.

A urine test that could change the course of bladder cancer care
A new study published in Cell from a team of investigators from the Stanford Departments of Urology and Radiation Oncology, in close collaboration with colleagues from Stanford Cancer Institute, offers a powerful new approach: using a non-invasive urine test to determine, at a molecular level, who benefits from additional therapy—and who does not.